Division of Gastroenterology and Hepatology, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland.
Section of Gastroenterology, Boston Medical Center, Boston University School of Medicine, Boston, Massachusetts.
Inflamm Bowel Dis. 2019 Apr 11;25(5):820-830. doi: 10.1093/ibd/izy327.
Over the last 2 decades, novel therapies targeting several immune pathways have been developed for the treatment of patients with inflammatory bowel disease (IBD). Although anti-tumor necrosis factor (anti-TNF) agents remain the firstline treatment for moderate to severe Crohn's disease and ulcerative colitis, many patients will require alternative agents, due to nonresponse, loss of response, or intolerance of anti-TNFs. Furthermore, patients may request newer therapies due to improved safety profiles or improved administration (ie, less frequent injection, oral therapy). This review will focus on new and emerging therapies for the treatment of IBD, with a special focus on their adverse effects. Although many of the agents included in this paper have been approved for use in IBD, a few are still in development but have been shown to be effective in phase II clinical trials. 10.1093/ibd/izy327_video1 izy327.video1 5967364908001.
在过去的 20 年中，已经开发出了针对几种免疫途径的新型疗法，用于治疗炎症性肠病（IBD）患者。虽然抗肿瘤坏死因子（anti-TNF）药物仍然是中重度克罗恩病和溃疡性结肠炎的一线治疗药物，但由于对 anti-TNFs 的无反应、失去反应或不耐受，许多患者需要替代药物。此外，由于安全性更好或给药方式（即更频繁的注射、口服治疗）的改善，患者可能会要求使用新的治疗方法。本文将重点介绍用于治疗 IBD 的新型和新兴疗法，特别关注它们的不良反应。虽然本文中包含的许多药物已被批准用于 IBD，但少数药物仍在开发中，但在 II 期临床试验中已显示出有效性。
